Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection | Zendy

Pedro M. M. Mesquita | Zendy; Rachna Rastogi | Zendy; Theodore J. Segarra | Zendy; Ryan S. Teller | Zendy; N. Merna Torres | Zendy; Adam M. Huber | Zendy; Patrick F. Kiser | Zendy; Betsy C. Herold | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection

Author(s) -

Pedro M. M. Mesquita,

Rachna Rastogi,

Theodore J. Segarra,

Ryan S. Teller,

N. Merna Torres,

Adam M. Huber,

Patrick F. Kiser,

Betsy C. Herold

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks097

Subject(s) - tenofovir , herpes simplex virus , prodrug , pharmacology , microbicides for sexually transmitted diseases , virology , drug , virus , medicine , drug delivery , human immunodeficiency virus (hiv) , chemistry , population , organic chemistry , environmental health , health services

A safe and effective topical prevention strategy will likely require sustained delivery of potent antiviral drugs and a delivery system that simultaneously maximizes drug distribution and overcomes the behavioural challenges related to adherence. Activity against HIV and herpes simplex virus (HSV) would be advantageous, given the epidemiological link between the two pathogens. We hypothesize that tenofovir disoproxil fumarate (tenofovir DF), a prodrug of tenofovir, may be more potent than tenofovir and ideal for sustained intravaginal ring (IVR) delivery.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research